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Objective: using a rabbit vascular graft model we investigated the use of fibrin glue (FG), gelatin-resorcinol-formaldehyde
(GRF), and collagen (C) as a means of reducing suture hole bleeding.
Materials and methods: twenty-eight rabbits were divided into four groups: fibrin glue, gelatin-resorcinol-formaldehyde,
collagen and control. A 1 cm incision was made in the abdominal aortic wall of each animal. Incisions were covered with a
polytetrafluoroethylene patch sutured with a 7-0 polypropylene. Fibrin Glue, GRF, and C were applied to cover suture holes
in the groups 1, 2 and 3, respectively, but nothing in controls (group 4). The fibrin clot was allowed to achieve strength for 3
minutes before the clamps were reopened. After reopening the clamps, blood was collected from the surgical site using a
syringe for a total of 2 min.
Results: mean blood loss was significantly lower in the FG, GRF, and C compared with control group (p 0.0022,
p 0.0022, and p 0.0017, respectively). The volume of blood lost and the time of haemostasis in the group 1 (FG) was less
than those in groups 2 and 3 (GRF and C, respectively) (p 0.001). The haemostasis (defined 2 min later) was achieved
only in group 1 (FG) (p 0.00067).
Conclusions: FG, GRF and C all reduce blood loss. Fibrin glue containing factor XIII was the most effective.
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Haemostasis is particularly important in cardiovascu-
lar surgery. Great quantities of fibrin adhesive agents
are often required in patients with extensive anasto-
mosis and bleeding tendencies despite meticulous
operations to assure haemostasis.1±3 Topical haemo-
static agents include oxidised regenerated cellulose,
absorbable gelatin sponge with and without thrombin,
microfibrillar collagen, foam, fibrin sealants, commonly
produced with components from pooled human
blood, and various composites of these materials.4
Fibrin sealants (FSs) are haemostatic and adhesive
agents derived from pooled human plasma. Fibrin
sealants have been shown to be effective in vascular
procedures to seal suture holes, anastomoses, fistulas,
and raw surfaces.5±8 Fibrin sealants comprise different
amounts of fibrinogen, thrombin, aprotinin and factor
XIII.9,10 Factor XIII, activated by thrombin, catalyses
the formation of cross-links within the fibrin clot, and
a stable clot is formed at the site of application.11 This* Please address all correspondence to: Y. UÈ nluÈ , MD, AtatuÈ rk Mah.
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lytic protein, such as aprotinin.9 Major complications
of FS products appear to be rare, but anaphylactic
reaction has been described.12,13
Conventional topical haemostatic agents were
made of collagen (C), gelatin or cellulose.14 Gelatin-
Resorcinol-Formaldehyde(GRF)consistsofanadhesive
(gelatin and resorcinol) and a polymerising agent
(formaldehyde and glutaraldehyde).15
The purpose of this pilot study was to evaluate the
blood loss and the time to achieve haemostasis from
sutured patches treated with FG, GRF and C, and to
compare them with the untreated (control) group.
Materials and Methods
Animal preparation
Adult rabbit hybrids weighing 3±3.5 kg were used
in this study. The experiments were conducted in
accordance with the Guidelines for the Care and Use
of Laboratory Animals published by the Nationalll rights reserved.
442 Y. UÈ nluÈ et al.Institutes of Health (NIH Publication No. 86-23,
revised 1985).
Animals were premedicated with intramuscular
administration of 25 mg/kg ketamin HCl (Ketalar1,
Eczacõbas¸õ Warner Lambert licence by Parke-Davis,
Istanbul, Turkey). Venous access was obtained
through a 20-gauge intravenous catheter placed in a
large marginal vein in the ear. Anaesthesia was main-
tained with 10 mg/kg intravenous ketamine HCl.
Test agents
Fibrin glue (FG)
Fibrin Glue (Tisseel1 Kit ± IMMUNO AG. Vienna,
Austria) is made from four components: (1) highly
concentrated fibrinogen (total protein approximately
120 20 mg/mL), (2) aprotinin (3000 KIU/mL) (1 KIU
is equivalent to 1.11110ÿ3 trypsin inhibitor U), (3)
freeze-dried thrombin (500 IU/mL), and (4) calcium
chloride (40 mmol/L). The fibrinogen is obtained
from human donor plasma. After preheating to
37 C, the fibrinogen is dissolved in bovine aprotinin,
and the dried human thrombin is reconstituted in
calcium chloride. The two solutions are then drawn
up into separate syringes that are loaded onto a
double-barrelled syringe holder designed to mix and
apply the components simultaneously. The reconstitu-
tion procedure takes 10±15 min, and the components
should be used within 4 h. The reconstituted adhesive
contains 70±110 mg/mL of fibrinogen, 2±9 mg/mL of
fibronectin (cold-insoluble globulin), 10±50 U/mL of
factor XIII (1 U is that amount of factor XIII that is
contained in 1 mL of citrated, pooled human plasma),
and 40±120 mg/mL of plasminogen.
Gelatin-resorcinol-formaldehyde (GRF)
GRF (Cardial1, Saint-Etienne Cedex 9, France) con-
sists of an adhesive (gelatin and resorcinol) in a tube,
and a polymerising agent (formaldehyde and glutar-
aldehyde) in an amber glass vial. The product is
supplied with a specially designed syringe tip for
accurate application of the polymerising agent.
Collagen (C)
Collagen (400 mg) (Colgen1 Powder, Avenuejean
Jaures-Aubervilliers, France) is natural, non-
denatured collagen, which is a resorbable haemostatic.
The collagen powder requires no special preparation.
It can be `dusted' onto open oozing surfaces to control
bleeding or to bond two opposing surfaces (flaps).Eur J Vasc Endovasc Surg Vol 23, May 2002Surgical procedure
A bolus intravenous injection of heparin (100 U/kg)
(Liquemin1, F. Hoffman-La Roche, Basel, Switzerland)
was administered to each rabbit to achieve full anti-
coagulation. A single surgeon operated on all animals.
The abdomen was prepped and a paramedian skin
incision was made. Then, a midline incision was
made in the fascia. Patency of the abdominal aorta
was measured using a high-frequency (8 MHz) pulsed
wave Doppler ultrasound (Microdop, norm. IEC
601-1, France). After adequate heparinisation, blood
flow to the abdominal aorta was interrupted using
surgical clamps placed approximately 3 cm apart.
Next, a 1-cm incision was made in the abdominal
aorta using a scalpel blade. The incision was covered
with a spindle-shaped polytetrafluoroethylene (PTFE)
patch (10 3 mm) (Gore-Tex1, WL Gore & Associates,
Inc. Pulzbrunn, Germany), which was sewn into place
using approximately 16 stitches of polypropylene
suture 7-0 (Ethicon1, Prolene-Blue, Norderstedt,
Germany). After the patches were secure, clamps
were released briefly to ensure blood spilled from
the suture holes. Clamps were closed again and the
patch was treated according to the following protocol.
After reopening the clamps, patency of the vessel was
remeasured using a high-frequency pulsed wave
Doppler ultrasound.
The rabbits in all groups (n 28) were operated, and
PTFE patches were attached using 7-0 polypropylene
suture. Fibrin glue, GRF and C were applied to cover
suture holes in the groups 1, 2 and 3, respectively, but
nothing in control group 4. The fibrin clot was allowed
to achieve strength for 3 min before the clamps were
reopened. After reopening the clamps, blood was col-
lected from the surgical site using a syringe for a total
of 2 min.
The effects of the topical haemostatic agents were
investigated on haemostasis and blood loss. There-
fore, the blood loss and haemostasis were compared
between the groups.
Additionally, the volume of blood lost and the
time of hemostasis in the group 1 (FG) were compared
with those in the groups 2 (GRF), 3 (C) and 4 (control).
Statistical analysis
All results were expressed as the mean the standard
error of the mean. Comparisons between the groups
were made using Kruskal±Wallis test for blood
loss, and Kolmogorov Smirnov one sample test
for haemostasis. Mann±Whitney U-test was used for
Table 1. Haemostasis and blood loss in all groups, and statistical comparison of Mann±Whitney U-test between all groups.
Group Median (mL) Range (mL) Haemostasis (n) Fibrin glue (G1) GRF (G2) Collagen (G3) Control (G4)
Group 1 (Fibrin Glue, n 7) 1.50* 1.0±2.0 7** ± p 0.0016 p 0.0019 p 0.0022
Group 2 (GRF, n 7) 2.50 2.5±3.5 0 p 0.0016 ± p4 0.05 p 0.0022
Group 3 (Collagen, n 7) 3.00 2.5±5.0 0 p 0.0019 p4 0.05 ± p 0.0017
Group 4 (Control, n 7) 10.00 8.0±15.0 0 p 0.0022 p 0.0022 p 0.0017 ±
* p5 0.001, Kruskal±Wallis test.
** p 0.00067, Kolmogorov-Smirnov one sample test; GRF: Gelatin-resorcinol-formaldehyde; G1: Group 1; G2: Group 2; G3: Group 3;
G4: Group 4.
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than 0.05 was considered statistically significant.
Results
The mean blood loss was significantly lower in the FG,
GRF and C treated groups (1, 2 and 3, respectively)
when compared with the untreated (control) group 4
(Table 1). The volume of blood lost in group 1 (FG)
was significantly lower than that in groups 2 (GRF)
and 3 (C).
Haemostasis (7/7) (cessation of blood loss 2 min
later) was achieved only in group 1 (FG), but in the
other groups (GRF, C and control) it was not achieved
(0/21). This result was highly significant (p 0.00067)
using the Kolmogorov Smirnov one sample test
(Table 1).
As a result, the FG significantly reduced the time of
haemostasis and the volume of blood lost compared to
the other groups.
Discussion
In this study, when FG was applied to PTFE patches,
haemostasis was enhanced and the volume of blood
lost was reduced compared to controls.16
Fibrin sealant allows the immediate interaction
of fibrinogen and thrombin permitting the delivery
of fibrin onto the wound surface and interstices.17
It has been reported that fibrin adhesive agents
enhance agglutination and fibrin-clot formation at
the site of injury, and these agents are useful to
promote tissue adhesion and wound healing.6,14,18,19
In cardiovascular operations, great quantities of
fibrin adhesive agents are often used to reinforce
haemostasis.3,20±22 Despite their widespread use,
some of the fibrin adhesive agents present many pro-
blems for surgeons, as potential complications.7,23,24
The use of FS, as with any plasma product, carries
a theoretical risk of pathogen transmission. The
associated risk of viral transmission from commercial
FSs is lower than for blood transfusion.7,25 Plasmaprotein purification methods have been developed
that virtually eliminate the hepatitis and human
immunodeficiency virus (HIV) risks.23,24
Because aprotinin (FSs contain aprotinin) is a poly-
peptide extracted from bovine organs, an immuno-
logic reaction after its administration to humans is
always possible. Routine administration of aprotinin
may become problematic. Therefore, to reduce the risk
of allergic reactions, it was recommended that a test
dose of 10 000 KIU (1.4 mg) be associated with the use
of H1 and H2 blockers.
26
Of the ingredients used to prepare FS, cryoprecipi-
tate and bovine thrombin are antigenic and could
potentially cause an anaphylactic reaction. Use of the
most pure preparations is likely to minimise or elim-
inate antibody problems.27
Fibrin glue is nontoxic, biodegradable, promotes
local tissue growth and repair, and may prevent adhe-
sions.22 However, there are continued questions about
the potential clinical, toxic and carcinogenic effects of
the formaldehyde component of GRF in general.28
Moreover, Collagen-based products have somewhat
unsatisfactory handling properties, and their use
often requires concurred manual tamponade.4
Preventing suture hole bleeding can reduce blood
loss and improve blood conservation, thus reducing
the need for blood transfusion, and reduces or elim-
inates the potential risk of viral transmission asso-
ciated with blood transfusion.7,29,30
Dickneite and colleagues7 demonstrated that
blood loss with FS containing factor XIII was signifi-
cantly lower than the one with FS depleted of factor
XIII. In their study, the presence of factor XIII
enhanced the efficacy of FS by accelerating haemo-
stasis and reducing blood loss. In addition, the FS
containing factor XIII was reduced the time to haemo-
stasis. Also, Shen and Lorand11 have shown that the
fibrin clot is stabilised by factor XIII-dependent fibrin
cross linking and any clot formed from FS lacking
factor XIII would not be stabilised by this type of
cross linking.
All these findings suggest that FSs containing factor
XIII have both the efficacy of the FS and the measur-
able advantage.Eur J Vasc Endovasc Surg Vol 23, May 2002
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time of haemostasis with FG containing factor XIII
was significantly lower than those with GRF and C.
Fibrin glue is an important adjunct for surgeons
who endeavour both to achieve satisfactory haemo-
stasis and to reduce blood loss, while GRF and C, as
topical haemostatic agents, are only effective on the
blood loss. Fibrin glue is superior to GRF and C as it
reduced the blood loss and provided good haemo-
stasis. Another criterion, which makes FG superior, is
the identified potential complications of GRF.
In conclusion, fibrin sealants as topical haemostatic
agents reduce both the blood loss and the time of
hemostasis. Also, haemorrhage can rapidly be con-
trolled with the using of these agents.
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